Anna Onisiforou

Featured in: Favicon

Articles

Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer′s Risk in Diabetes Type II via Dual Actions: Tackling Disease Pathways and Environmental Herpesvirus Triggers

1 month ago | biorxiv.org | Andrea Georgiou |Panos Zanos |Anna Onisiforou

AbstractAlzheimer′s disease (AD) and Diabetes Mellitus Type II (DM2) share overlapping pathological mechanisms, with DM2 increasing AD risk. Disease-modifying therapies (DMTs) for DM2, including Metformin and Semaglutide, have been explored for neuroprotection, yet their efficacy in AD remains unclear.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.